Introduction
============

Excluding dermatologic cancers, breast cancer is the most frequently diagnosed cancer among US women. In 2017, invasive breast disease is expected to account for 30% of all newly diagnosed cancers in women and to cause 16% of deaths in those affected.[@b1-bctt-9-559] The current treatment regimen for breast cancer is multidisciplinary. Depending on the stage and histology of the cancer, patients may receive a combination or all of the following modalities: surgery, radiotherapy, chemotherapy, hormonal therapy, targeted therapy, and immunotherapy. Although a comprehensive approach is often necessary in order to eradicate disease, breast cancer treatment protocols can sometimes prove too cumbersome, distressing, and even, at times, toxic for the patient to complete successfully. Treatment noncompliance or the premature discontinuation of therapy has been reported to negatively affect outcomes.[@b2-bctt-9-559]--[@b5-bctt-9-559] Given these obstacles, as well as the high mortality rate of aggressive breast cancers, consideration of other effective therapies is thus of paramount importance.

Statins, also known as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are a class of lipid-lowering medications that block the conversion of HMG-CoA to mevalonic acid, which under normal circumstances ultimately yields cholesterol as a part of the mevalonate pathway. Historically, statins have been marketed and prescribed for the primary and secondary prevention of cardiovascular disease, and their current use is widespread. According to a report by the Centers for Disease Control and Prevention in 2014, 23.6 and 38.9% of women over 45 or 75 years, respectively, were taking statins.[@b6-bctt-9-559] Due to their growing popularity over the past 2 decades, generic statin medications now cost \<\$12/month and represent an affordable lipid-lowering agent for individuals at risk of developing heart disease or heart disease-related complications.[@b7-bctt-9-559] Beyond their cardiovascular effects, however, statins have been reported to have possible benefits regarding immunomodulation in autoimmune diseases and organ transplantation, induction of bone marrow stimulation, and inhibition of cancer progression.[@b8-bctt-9-559]--[@b11-bctt-9-559] Their role in breast cancer recurrence and mortality is of particular interest. Preclinical and clinical data exist to support a beneficial role for their use in breast cancer management. However, other studies are less promising and argue against the prescription of statins for purposes not related to cardiovascular disease. Furthermore, results differ depending on the type of statin used, ie, lipophilic (simvastatin, lovastatin, and atorvastatin) vs hydrophilic (pravastatin, rosuvastatin, and fluvastatin). In the following article, we summarize current findings regarding the effect of statins on breast cancer clinical outcomes and provide insight on potential future studies needed for this important topic.

Clinical data regarding the use of statins in breast cancer management
======================================================================

Several studies suggest a role for statin therapy in breast cancer management; however, the type of statin used, when it is used with respect to time of diagnosis, duration of treatment, follow-up time, and patient cohort characteristics differ significantly in these reports. Thus, it is important to consider all the findings together.

Statins and breast cancer recurrence rates and prognosis
========================================================

Clinical data suggest that statins reduce breast cancer recurrence rates when administered postdiagnostically. In one prospective study of 1,945 early-stage breast cancer survivors, initiation of statin use \<3 years after diagnosis was independently associated with decreased 5-year breast cancer recurrence rates in a duration-dependent manner. It is important to note that 98% of the statins prescribed were lipophilic statins, ie, lovastatin (84.4%), simvastatin (10.9%), and atorvastatin (2.5%).[@b12-bctt-9-559] Similarly, in a nationwide, population-based prospective study, Ahern et al found that in women diagnosed with stages I--III breast cancers, patients who took simvastatin in particular after diagnosis experienced 10 fewer breast cancer recurrences per 100 women after 10 years of follow-up. Low outcome frequency precluded the authors from modeling recurrence associations for the exclusive use of the other lipophilic statins. After accounting for potential confounders, hydrophilic statin use was not associated with recurrence outcomes.[@b13-bctt-9-559] Findings from Manthravadi et al's[@b14-bctt-9-559] meta-analysis were in agreement with those from the study by Ahern et al, namely, that a recurrence-free survival benefit was observed for lipophilic statin use only.

Even short-term statin therapy administered after diagnosis may be beneficial. In a retrospective study of 703 stage II/III breast cancer patients, Chae et al found that statin use for as little as 6 months after the initial diagnosis was independently associated with a reduced likelihood of recurrence out to 4.5 years, especially when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Interestingly, the majority of patients in this study took atorvastatin (60.2%), followed by simvastatin (17.2%), lovastatin (10.2%), and pravastatin (7.8%), perhaps suggesting that no one statin is superior regarding breast cancer recurrence outcomes.[@b15-bctt-9-559] This idea is supported by Boudreau et al, who, in a prospective cohort study of 4,216 women diagnosed with stage I/II breast cancer, reported similar adjusted outcomes for a second breast cancer event (SBCE) between lipophilic and hydrophilic statin users. For all statin users, the authors found a nonsignificant reduced risk of an SBCE.[@b16-bctt-9-559] Finally, regarding recurrence, in a retrospective study with the most extensive follow-up, Sakellakis et al[@b17-bctt-9-559] found that statin users had a longer mean relapse-free survival by \~6 years, and younger statin users (\<56 years old) were observed to benefit the most by \~10 years as compared with other users (refer [Table 1](#t1-bctt-9-559){ref-type="table"} for an overview of the association between statin use and risk of recurrence after multivariate analysis).

The effect of statins on progression-free survival (PFS), overall survival (OS), and disease-specific survival for inflammatory breast cancer (IBC), an especially aggressive subtype, was retrospectively examined. Interestingly, and contrary to most reports for other breast cancers, a longer PFS was independently observed for patients taking hydrophilic or weakly lipophilic statins after initial evaluation, ie, atorvastatin (29%), pravastatin (9%), and rosuvastatin (1%), while lipophilic statins were not associated with any outcome parameters.[@b18-bctt-9-559] Note that atorvastatin in the latter study was classified as a weakly lipophilic statin and was thus analyzed with hydrophilic statins. Thus, specific types of statins may be more beneficial in patients with aggressive breast cancers.

Statins and breast cancer mortality
===================================

Various other studies suggest a survival benefit for breast cancer patients who take statins. Murtola et al followed a large cohort of Finnish patients for a median of 3.25 years and found that both pre- and postdiagnostic statin use in both localized and metastatic cases were associated with a decreased risk of death from breast cancer. Furthermore, this finding was dose dependent and time dependent for users taking statins prior to diagnosis. These parameters could not be adequately evaluated for postdiagnostic use due to a likely healthy adherer bias. Interestingly, when results were stratified according to statin type, hydrophilic statins had a benefit only when taken postdiagnostically and timing did not matter for lipophilic statins.[@b19-bctt-9-559] In a population-based cohort study, Cardwell et al[@b20-bctt-9-559] evaluated postdiagnostic statin use in particular and found a significant reduction in both breast cancer and all-cause mortality for simvastatin only. No associations were found for any other type of statin. Zhong et al's[@b21-bctt-9-559] meta-analysis found that statins improved all-cause mortality for breast cancer patients when taken prior to diagnosis. Similarly, in Manthravadi et al's[@b14-bctt-9-559] recent meta-analysis of eight and six studies, statin users had an improved OS and cancer-specific survival, respectively. Conversely, a prospective Scottish cohort study found no association between statin use and all-cause or breast cancer-specific mortality. However, a weak, nonsignificant reduction in breast cancer-specific mortality was observed in patients who took simvastatin specifically at relatively any time in relation to diagnosis[@b22-bctt-9-559] (refer [Table 2](#t2-bctt-9-559){ref-type="table"} for an overview of the association between statin use and risk of breast cancer-specific death after multivariate analysis).

In conclusion, since a breast cancer event cannot realistically be predicted for any one patient, we should consider primarily the effect of postdiagnostic statin use on breast cancer clinical outcomes. Nonrandomized studies suggest a clear recurrence benefit for breast cancer patients taking lipophilic statins after diagnosis, although hydrophilic or weakly lipophilic statins appear to be most effective for IBC patients in particular. Evidence is less clear regarding statins and breast cancer mortality, although a role for simvastatin specifically is apparent.

Statins and breast cancer incidence
===================================

Given the promising results detailed earlier, an important next step would be to evaluate the role of statins in breast cancer prevention. Another crucial consideration is whether or not statins have carcinogenic properties after long-term use.

Since randomized statin trials did not include breast cancer incidence as a primary endpoint, meta-analyses have been conducted to examine this relationship and they have reported no association between statin use and breast cancer risk. Studies by Bonovas et al[@b23-bctt-9-559] and Undela et al[@b24-bctt-9-559] examined breast cancer in particular, while others investigated cancers in general, including breast cancer[@b25-bctt-9-559]--[@b28-bctt-9-559] (refer [Table 3](#t3-bctt-9-559){ref-type="table"} for an overview of these meta-analyses). When the relationship between statins and breast cancer risk was examined as part of the Women's Health Initiative, a large US prevention study that enrolled \>160,000 postmenopausal women aged 50--79 years over a period of 15 years; however, use of lipophilic statins was independently associated with a reduction in late-stage breast cancer diagnoses, specifically for those with estrogen receptor (ER)-positive cancers.[@b29-bctt-9-559]

When the incidence of invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) was examined retrospectively in association with statin use, however, McDougall et al found that women taking statins for ≥10 years had an increased risk of invasive breast disease compared to patients who had never used statins. Furthermore, stratifying by ER status, the authors found twofold increases in risk for both ER+ IDC and ILC in the statin cohort. It is unclear, though, if a prolonged history of high cholesterol is the actual culprit, as the risk of developing breast cancer was stronger for patients with higher cholesterol levels.[@b30-bctt-9-559]

Arun et al conducted a prospective short-term prevention study to evaluate the effect of atorvastatin on biomarkers in the breast tissue and serum of women at an increased risk of breast cancer, ie, those with a previous history of carcinoma in situ or atypical hyperplasia, or an increased projected breast cancer risk given by accepted models. After 3 months, patients who were randomized to take atorvastatin had significantly decreased levels of serum C-reactive protein, cholesterol, and low-density lipoprotein. Atorvastatin metabolites were found in breast biopsies. Other tested tissue biomarkers -- Ki-67, bcl-2, EGFR, and pEGFR -- were not significantly different between the two groups.[@b31-bctt-9-559] Thus, atorvastatin may help reduce inflammation and does accumulate in breast tissue.

Future studies
==============

Various breast cancer in vitro and animal studies have attempted to elucidate the mechanism by which statins exert their antitumor effects. In particular, the effect of statins on breast cancer invasion, migration, proliferation, apoptosis, and radiosensitivity has been studied in detail.

Preclinical data often direct clinical research, and thus, it is important to remain up to date regarding recent laboratory findings and their potential implications in the clinical arena. In particular, evidence suggests a potential role for statins in the neoadjuvant setting and/or in combination with other agents.

Statins in the neoadjuvant setting
==================================

An important question is whether or not statins have the potential to reduce tumor proliferation and/or volume neoadjuvantly. To help answer this question, Garwood et al[@b32-bctt-9-559] randomized patients with a diagnosis of ductal carcinoma in situ or stage I breast cancer to a perioperative trial of high-dose (80 mg/day) or low-dose (20 mg/day) fluvastatin 3--6 weeks prior to surgery. The authors then examined the effect of this treatment on tumor proliferation (Ki-67 and MRI tumor volume), apoptosis (cleaved caspase-3), and inflammation (C-reactive protein). Fluvastatin significantly reduced the proliferation of high-grade tumors by 7.2%, and more high-grade than low-grade tumors had an increase in apoptosis (60 vs 13%). Results were significant regardless of whether the patients received the high-dose or the low-dose regimen. Fluvastatin also decreased median tumor size by 12.7%, although this finding was not significant. Additional studies are warranted to determine whether or not statins can prove an effective neoadjuvant therapy for high-grade breast cancers.

It would be ideal to have a biomarker that could predict neoadjuvant tumor response to statin therapy and help select patients who would benefit the most from it. Bjarnadottir et al analyzed statin-induced effects on tumor proliferation in association with HMG-CoA reductase (HMGCAR) expression in patients with invasive breast cancer.[@b33-bctt-9-559] Patients were given high-dose atorvastatin (80 mg/day) for 2 weeks prior to surgery. The authors found a significant decrease (7.6%) in Ki-67 expression specifically for tumors expressing HMG-CAR in the pretreatment sample. Furthermore, posttreatment Ki-67 expression was inversely correlated to posttreatment HMGCAR levels, implying that HMGCAR can be used as a predictive biomarker for statin tumor response.[@b33-bctt-9-559]

Role for statins in inducing chemosensitivity
=============================================

The studies mentioned earlier strongly suggest that statins alone facilitate apoptosis in breast cancer cells. Their effectiveness in combination with other therapies, however, is yet to be explored. Koyuturk et al[@b34-bctt-9-559] report that one of the mechanisms by which statins induce apoptosis is activation of the JNK-signaling pathway. Since inhibition of JNK activation is a major mechanism behind tumor resistance to cisplatin and vinblastine,[@b35-bctt-9-559],[@b36-bctt-9-559] perhaps the addition of statins to either of these drugs could help overcome any chemoresistance. Although these chemotherapies are more commonly used in the treatment of Hodgkin's lymphoma, non-small-cell lung cancer, bladder cancer, melanoma, head and neck cancer, and cervical cancer, it would be worth examining whether or not statins can potentiate tumor response to more conventional breast cancer chemotherapies, eg, docetaxel, doxorubicin, and cyclophosphamide (TAC).

Role for statins in preventing and managing breast cancer metastases
====================================================================

Although most of the studies discussed thus far included only patients with stage 0--III breast cancer diagnoses, work by Denoyelle et al[@b37-bctt-9-559] and Alonso et al[@b38-bctt-9-559] suggests a potential role for cerivastatin and lovastatin in the prevention of metastases in triple-negative breast cancer (TNBC) and sarcomatoid mammary carcinoma, respectively. The former found that in the aggressive TNBC cell line MDA-MB-231, cerivastatin inhibited the production of cholesterol precursors farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are responsible for translocation of Ras and Rho, respectively, to the cell membrane. Under normal circumstances, this final step allows the initiation of cell proliferation and migration. The introduction of cerivastatin in vitro, however, inhibited both cell proliferation and invasion through Matrigel (Becton Dickinson, Franklin Lakes, NJ, USA) and induced a loss of cell attachment in a dose-dependent manner. Alonso et al[@b38-bctt-9-559] found in a murine animal model of F3II sarcomatoid mammary carcinoma that lovastatin treatment prolonged tumor latency, reduced tumor formation, and decreased metastatic dissemination. Given these results, studies examining the effect of statins on clinical outcomes for metastatic breast cancer patients specifically may be warranted.

Role for statins in combination with radiotherapy
=================================================

A potential role for statins as a radiosensitizer for aggressive breast cancers has been suggested in both the basic science and the clinical realms. We have shown that simvastatin radiosensitizes various aggressive breast cancer subtypes in vitro -- namely, IBC cell lines MDA-IBC3, Sum149, and Sum190, as well as the aggressive non-IBC TNBC cell line Sum159 -- as evidenced by monolayer and mammosphere-based clonogenic assays. Furthermore, our findings were supported on clinical grounds, as statins were associated with a significant decrease in locoregional recurrence (LRR) rates for stage III IBC patients who underwent adjuvant radiotherapy. The actuarial 2- and 5-year local control rates for patients in the no-statin group were 76 and 69%, respectively, and for patients in the statin group were 92 and 85%, respectively.[@b39-bctt-9-559]

Resistance to radiation therapy resulting in LRR predicts a decreased OS.[@b40-bctt-9-559] TN IBC and TNBC have especially high 5-year actuarial rates of local failure after radiotherapy: 11--35 and 45%, respectively.[@b41-bctt-9-559],[@b42-bctt-9-559] This aggressive IBC phenotype is proposed to be caused by an enriched population of stem-like cells within these tumors.[@b43-bctt-9-559]--[@b45-bctt-9-559] Since statins have been shown to decrease normal tissue damage following radiotherapy,[@b46-bctt-9-559]--[@b48-bctt-9-559] they may serve a dual purpose for patients with aggressive breast cancers by, 1) radiosensitizing the tumor, and 2) permitting more aggressive protocols in the hope of further reducing LRR.

Conclusion
==========

Statins represent a new potential therapy to improve local control and provide a benefit for patients with breast cancer. Future studies evaluating the role of statins neoadjuvantly, in combination with chemotherapies, and as a radiosensitizer are required. It is unclear if any particular statin performs exceptionally, although the prevalence of simvastatin in these studies favors better outcomes in patients with breast cancer.
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###### 

Overview of the association between statin use and risk of recurrence after multivariate analysis

  Study                                Type                N                    Stage        Statins                                                  Recurrence        
  ------------------------------------ ------------------- -------------------- ------------ -------------------------------------------------------- ------------ ---- --------
  Kwan et al[@b12-bctt-9-559]          Prospective         1,945                I--IIIA      Lipophilic (97.8%)                                                    RR   95% CI
  Hydrophilic (2.2%)                   \>100 days          0.67                 0.39--1.13                                                                              
  \>2 years                            0.38                0.12--1.19                                                                                                   
  Ahern et al[@b13-bctt-9-559]         Prospective         18,769               I--III       Lipophilic (77.6%), simvastatin (71.7%)                               HR   95% CI
  Hydrophilic (22.3%)                  5-Year lipophilic   0.7                  0.53--0.92                                                                              
  5-Year simvastatin                   0.62                0.46--0.84                                                                                                   
  5-Year hydrophilic                   1.1                 0.7--1.80                                                                                                    
  10-Year lipophilic                   0.73                0.6--0.89                                                                                                    
  10-Year simvastatin                  0.7                 0.57--0.86                                                                                                   
  10-Year hydrophilic                  1.2                 0.79--1.7                                                                                                    
  Chae et al[@b15-bctt-9-559]          Retrospective       703                  II--III      Lipophilic (87.6%), atorvastatin (60.2%)                              HR   95% CI
  Hydrophilic (12.4%)                  Statins only        0.4                  0.24--0.67                                                                              
  Statins + ACEi/ARBs                  0.3                 0.15--0.61                                                                                                   
  Boudreau et al[@b16-bctt-9-559]      Prospective         4,216                I--IIB       Lipophilic, simvastatin (60.39%), fluvastatin (49.34%)                HR   95% CI
  Hydrophilic (3.63)                   \<1 year            0.94                 0.51--1.75                                                                              
  1--2.9 years                         0.66                0.34--1.30                                                                                                   
  3+ years                             0.77                0.42--1.41                                                                                                   
  Trend                                0.89                0.74--1.08                                                                                                   
  Sakellakis et al[@b17-bctt-9-559]    Retrospective       610                  I--III       Lipophilic (64%), atorvastatin (45%)                                  HR   95% CI
  Hydrophilic (16%)                    All statin users    0.58                 0.36--0.94                                                                              
  Brewer et al[@b18-bctt-9-559]        Retrospective       73                   III (IBC)    Lipophilic (39.7%)                                                    HR   95% CI
  Hydrophilic (60.3%)                  Hydrophilic only    0.49                 0.28--0.84                                                                              
  Lacerda et al[@b39-bctt-9-559]       Retrospective       53                   III (IBC)                                                                          HR   95% CI
                                       All statin users    0.4                  0.16--1.00                                                                              
  Manthravadi et al[@b14-bctt-9-559]   Meta-analysis       75,684; 14 studies   I--IV        All                                                                   HR   95% CI
  All statins (10 studies)             0.64                0.53--0.79                                                                                                   
  Lipophilic (three studies)           0.72                0.59--0.89                                                                                                   
  Hydrophilic (three studies)          0.8                 0.44--1.46                                                                                                   

**Abbreviations:** ACEi, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CI, confidence interval; HR, hazard ratio; IBC, inflammatory breast cancer; N, number; RR, relative risk.

###### 

Overview of the association between statin use and risk of breast cancer-specific death after multivariate analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Type                        N                    Stage                       Statins                                   Risk of breast cancer death   HR     CI           Notes
  ------------------------------------ --------------------------- -------------------- --------------------------- ----------------------------------------- ----------------------------- ------ ------------ ----------------
  Murtola et al[@b19-bctt-9-559]       Prospective                 31,236               All (local vs metastatic)   Simvastatin (48.9%)                       Prediagnostic statin use      0.46   0.38--0.55   

  Atorvastatin (36.3%)\                Postdiagnostic statin use   0.54                 0.44--0.67                                                                                                              
  fluvastatin (20.2%)                                                                                                                                                                                           

  Cardwell et al[@b20-bctt-9-559]      Prospective                 17,880               All                         Not specified                             All statins                   0.84   0.68--1.04   Postdiagnostic

  Simvastatin only                     0.79                        0.63--1                                                                                                                                      

  Mc Menamin et al[@b22-bctt-9-559]    Prospective                 15,140               All                         Lipophilic (68.1%), simvastatin (67.8%)   All statins                   0.95   0.79--1.15   Postdiagnostic

  Hydrophilic (35.3%)                  Simvastatin only            0.89                 0.73--1.08                                                                                                              

  Manthravadi et al[@b14-bctt-9-559]   Meta-analysis               75,684; 14 studies   I--IV                       All                                       Six studies                   0.7    0.46--1.06   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** CI, confidence interval; HR, hazard ratio; N, number.

###### 

Overview of meta-analyses carried out to determine the relationship between statins and breast cancer incidence

  Study                                  Year   Relative risk   95% CI
  -------------------------------------- ------ --------------- ------------
  Bonovas et al[@b23-bctt-9-559]         2005   1.03            0.93--1.14
  Dale et al[@b25-bctt-9-559]            2006   1.02            0.97--1.07
  Browning and Martin[@b26-bctt-9-559]   2007   1.01            0.79--1.3
  Kuoppala et al[@b27-bctt-9-559]        2008   1.04            0.74--19
  Baigent et al[@b28-bctt-9-559]         2010   1.07            0.84--1.38
  Undela et al[@b24-bctt-9-559]          2012   0.99            0.94--1.04

**Abbreviation:** CI, confidence interval.
